Using Personalized Immunotherapies to Advance Melanoma Treatment

Abdel-Malek, Z. A., Kadekaro, A. L., & Swope, V. B. (2010). Stepping up melanocytes to the challenge of UV exposure. Pigment Cell & Melanoma Research, 23(2), 171–186. https://doi.org/10.1111/j.1755-148X.2010.00679.x

Andtbacka, R. H. I., Curti, B. D., Kaufman, H., Daniels, G. A., Nemunaitis, J. J., Spitler, L. E., Hallmeyer, S., Lutzky, J., Schultz, S. M., Whitman, E. D., Zhou, K., Karpathy, R., Weisberg, J. I., Grose, M., & Shafren, D. (2015). Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. Journal of Clinical Oncology, 33(15_suppl), 9030–9030. https://doi.org/10.1200/jco.2015.33.15_suppl.9030

Antohe, M., Nedelcu, R. I., Nichita, L., Popp, C. G., Cioplea, M., Brinzea, A., Hodorogea, A., Calinescu, A., Balaban, M., Ion, D. A., Diaconu, C., Bleotu, C., Pirici, D., Zurac, S. A., & Turcu, G. (2019). Tumor infiltrating lymphocytes: The regulator of melanoma evolution (Review). Oncology Letters, 17(5), 4155–4161. https://doi.org/10.3892/ol.2019.9940

Au, G., Lindberg, A., Barry, R., & Shafren, D. (2005). Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. International Journal of Oncology. https://doi.org/10.3892/ijo.26.6.1471

Aurelian, L. (2016). Oncolytic viruses as immunotherapy: Progress and remaining challenges. OncoTargets and Therapy, 9, 2627–2637. https://doi.org/10.2147/OTT.S63049

Bagchi, S., Yuan, R., & Engleman, E. G. (2021). Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 16(1), 223–249. https://doi.org/10.1146/annurev-pathol-042020-042741

Bradley, S., Jakes, A., Harrington, K., Pandha, H., Melcher, A., & Errington-Mais, F. (2014). Applications of coxsackievirus A21 in oncology. Oncolytic Virotherapy, 47. https://doi.org/10.2147/OV.S56322

Brady, J., Kashlan, R., Ruterbusch, J., Farshchian, M., & Moossavi, M. (2021). Racial Disparities in Patients with Melanoma: A Multivariate Survival Analysis. Clinical, Cosmetic and Investigational Dermatology, 14, 547–550. https://doi.org/10.2147/CCID.S311694

Chu, Y., Liu, Q., Wei, J., & Liu, B. (2018). Personalized cancer neoantigen vaccines come of age. Theranostics, 8(15), 4238–4246. https://doi.org/10.7150/thno.24387

De Miguel, M., & Calvo, E. (2020). Clinical Challenges of Immune Checkpoint Inhibitors. Cancer Cell, 38(3), 326–333. https://doi.org/10.1016/j.ccell.2020.07.004

Delhalle, S., Bode, S. F. N., Balling, R., Ollert, M., & He, F. Q. (2018). A roadmap towards personalized immunology. Npj Systems Biology and Applications, 4(1), 1–14. https://doi.org/10.1038/s41540-017-0045-9

Dobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022). Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment. International Journal of Molecular Sciences, 23(5), Article 5. https://doi.org/10.3390/ijms23052847

Everts, B., & Poel, H. (2005). Everts, B and van der Poel, HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 12: 141-161. Cancer Gene Therapy, 12, 141–161. https://doi.org/10.1038/sj.cgt.7700771

Feldman, S. A., Assadipour, Y., Kriley, I., Goff, S. L., & Rosenberg, S. A. (2015). Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. Seminars in Oncology, 42(4), 626–639. https://doi.org/10.1053/j.seminoncol.2015.05.005

Ferrucci, P. F., Pala, L., Conforti, F., & Cocorocchio, E. (2021). Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers, 13(6), Article 6. https://doi.org/10.3390/cancers13061383

Fukuhara, H., Ino, Y., & Todo, T. (2016). Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Science, 107(10), 1373–1379. https://doi.org/10.1111/cas.13027

Geukes Foppen, M. H., Donia, M., Svane, I. M., & Haanen, J. B. A. G. (2015). Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Molecular Oncology, 9(10), 1918–1935. https://doi.org/10.1016/j.molonc.2015.10.018

Goff, S. L., Smith, F. O., Klapper, J. A., Sherry, R., Wunderlich, J. R., Steinberg, S. M., White, D., Rosenberg, S. A., Dudley, M. E., & Yang, J. C. (2010). Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL. Journal of Immunotherapy, 33(8), 840. https://doi.org/10.1097/CJI.0b013e3181f05b91

Hall, M. S., Teer, J. K., Yu, X., Branthoover, H., Snedal, S., Rodriguez-Valentin, M., Nagle, L., Scott, E., Schachner, B., Innamarato, P., Hall, A. M., Blauvelt, J., Rich, C. J., Richards, A. D., Ceccarelli, J., Langer, T. J., Yoder, S. J., Beatty, M. S., Cox, C. A., … Pilon-Thomas, S. (2023). Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. Journal for Immunotherapy of Cancer, 11(10), e007288. https://doi.org/10.1136/jitc-2023-007288

Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R., Weber, J. S., Dronca, R., Mitchell, T. C., Patnaik, A., Zarour, H. M., Joshua, A. M., Zhao, Q., Jensen, E., Ahsan, S., Ibrahim, N., & Ribas, A. (2019). Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of Oncology, 30(4), 582–588. https://doi.org/10.1093/annonc/mdz011

Hong, J. J., Rosenberg, S. A., Dudley, M. E., Yang, J. C., White, D. E., Butman, J. A., & Sherry, R. M. (2010). Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy. Clinical Cancer Research, 16(19), 4892–4898. https://doi.org/10.1158/1078-0432.CCR-10-1507

Johnson, D. B., Puzanov, I., & Kelley, M. C. (2015). Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy, 7(6), 611–619. https://doi.org/10.2217/imt.15.35

Khoja, L., Butler, M. O., Kang, S. P., Ebbinghaus, S., & Joshua, A. M. (2015). Pembrolizumab. Journal for ImmunoTherapy of Cancer, 3(1), 36. https://doi.org/10.1186/s40425-015-0078-9

Kumar, A., Watkins, R., & Vilgelm, A. E. (2021). Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.690499

Kuryk, L., Bertinato, L., Staniszewska, M., Pancer, K., Wieczorek, M., Salmaso, S., Caliceti, P., & Garofalo, M. (2020). From Conventional Therapies to Immunotherapy: Melanoma Treatment in Review. Cancers, 12(10), Article 10. https://doi.org/10.3390/cancers12103057

Lauer, U. M., & Beil, J. (2022). Oncolytic viruses: Challenges and considerations in an evolving clinical landscape. Future Oncology, 18(24), 2713–2732. https://doi.org/10.2217/fon-2022-0440

Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017). Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncology, 3(6), 841–849. https://doi.org/10.1001/jamaoncol.2016.2064

Lee, L., Gupta, M., & Sahasranaman, S. (2016). Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. The Journal of Clinical Pharmacology, 56(2), 157–169. https://doi.org/10.1002/jcph.591

Mandal, R., & Chan, T. A. (2016). Personalized Oncology Meets Immunology: The Path Towards Precision Immunotherapy. Cancer Discovery, 6(7), 703–713. https://doi.org/10.1158/2159-8290.CD-16-0146

Mansh, M. (2011). Ipilimumab and Cancer Immunotherapy: A New Hope for Advanced Stage Melanoma. The Yale Journal of Biology and Medicine, 84(4), 381–389.

Mantwill, K., Klein, F. G., Wang, D., Hindupur, S. V., Ehrenfeld, M., Holm, P. S., & Nawroth, R. (2021). Concepts in Oncolytic Adenovirus Therapy. International Journal of Molecular Sciences, 22(19), Article 19. https://doi.org/10.3390/ijms221910522

Marelli, G., Howells, A., Lemoine, N. R., & Wang, Y. (2018). Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer. Frontiers in Immunology, 9. https://doi.org/10.3389/fimmu.2018.00866

Martin-Liberal, J., Kordbacheh, T., & Larkin, J. (2015). Safety of pembrolizumab for the treatment of melanoma. Expert Opinion on Drug Safety, 14(6), 957–964. https://doi.org/10.1517/14740338.2015.1021774

McCart, J. A., Wang, Z.-H., Xu, H., Hu, Y., Park, B., Alexander, H. R., & Bartlett, D. L. (2002). Development of a Melanoma-Specific Adenovirus. Molecular Therapy, 6(4), 471–480. https://doi.org/10.1006/mthe.2002.0692

Merhavi-Shoham, E., Itzhaki, O., Markel, G., Schachter, J., & Besser, M. (2017). Adoptive Cell Therapy for Metastatic Melanoma. The Cancer Journal, 23, 48–53. https://doi.org/10.1097/PPO.0000000000000240

Merlino, G., Herlyn, M., Fisher, D. E., Bastian, B. C., Flaherty, K. T., Davies, M. A., Wargo, J. A., Curiel-Lewandrowski, C., Weber, M. J., Leachman, S. A., Soengas, M. S., McMahon, M., Harbour, J. W., Swetter, S. M., Aplin, A. E., Atkins, M. B., Bosenberg, M. W., Dummer, R., Gershenwald, J. E., … Ronai, Z. A. (2016). The state of melanoma: Challenges and opportunities. Pigment Cell & Melanoma Research, 29(4), 404–416. https://doi.org/10.1111/pcmr.12475

Moser, J. C., Wei, G., Colonna, S. V., Grossmann, K. F., Patel, S., & Hyngstrom, J. R. (2020). Comparative-effectiveness of pembrolizumab vs. Nivolumab for patients with metastatic melanoma. Acta Oncologica, 59(4), 434–437. https://doi.org/10.1080/0284186X.2020.1712473

Nakajima, H., & Nakatsura, T. (2021). Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy. Immunological Medicine, 44(1), 10–15. https://doi.org/10.1080/25785826.2020.1785654

Paulson, K. G., Gupta, D., Kim, T. S., Veatch, J. R., Byrd, D. R., Bhatia, S., Wojcik, K., Chapuis, A. G., Thompson, J. A., Madeleine, M. M., & Gardner, J. M. (2020). Age-Specific Incidence of Melanoma in the United States. JAMA Dermatology, 156(1), 57–64. https://doi.org/10.1001/jamadermatol.2019.3353

Reynolds, C. R., Tran, S., Jain, M., & Narendran, A. (2022). Neoantigen Cancer Vaccines: Generation, Optimization, and Therapeutic Targeting Strategies. Vaccines, 10(2), Article 2. https://doi.org/10.3390/vaccines10020196

Robert, C., Schadendorf, D., Messina, M., Hodi, F. S., O’Day, S., & for the MDX010-20 investigators. (2013). Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control. Clinical Cancer Research, 19(8), 2232–2239. https://doi.org/10.1158/1078-0432.CCR-12-3080

Rogiers, A., Boekhout, A., Schwarze, J. K., Awada, G., Blank, C. U., & Neyns, B. (2019). Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. Journal of Oncology, 2019, e5269062. https://doi.org/10.1155/2019/5269062

Rotte, A., & Bhandaru, M. (2016). Immunotherapy of Melanoma. Springer.

Sankar, K., Ye, J. C., Li, Z., Zheng, L., Song, W., & Hu-Lieskovan, S. (2022). The role of biomarkers in personalized immunotherapy. Biomarker Research, 10(1), 32. https://doi.org/10.1186/s40364-022-00378-0

Stavrakaki, E., Dirven, C. M. F., & Lamfers, M. L. M. (2021). Personalizing Oncolytic Virotherapy for Glioblastoma: In Search of Biomarkers for Response. Cancers, 13(4), Article 4. https://doi.org/10.3390/cancers13040614

Tarhini, A., & Kudchadkar, R. R. (2018). Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. Cancer Treatment Reviews, 71, 8–18. https://doi.org/10.1016/j.ctrv.2018.09.005

Zablocka, T., Nikolajeva, A., Kreismane, M., Pjanova, D., & Isajevs, S. (2021). Addressing the importance of melanoma tumor infiltrating lymphocytes in disease progression and clinicopathological characteristics. Molecular and Clinical Oncology, 15(6), 1–8. https://doi.org/10.3892/mco.2021.2417

Zhao, Y., Deng, J., Rao, S., Guo, S., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., Li, X., Li, W., Gu, L., Sun, Y., Zhang, Z., Wen, Q., Xiao, Z., & Li, J. (2022). Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges. Cancers, 14(17), Article 17. https://doi.org/10.3390/cancers14174160